Cannabis Use Disorder Market Size, Trends, and Growth Forecast 2025-2032

Cannabis Use Disorder Market Size, Trends, and Growth Forecast 2025-2032

The Cannabis Use Disorder industry is undergoing significant evolution, driven by expanding medical research and rising awareness of substance abuse disorders. Strategic insights into the Cannabis Use Disorder market reveal accelerating efforts to address treatment gaps amid shifting regulatory frameworks and increasing investments toward innovative therapies.

Market Size and Overview
The cannabis use disorder market is estimated to be valued at USD 1.80 Bn in 2025 and is expected to reach USD 3.40 Bn by 2032, growing at a compound annual growth rate (CAGR) of 9.5% from 2025 to 2032.

This growth trajectory reflects increasing recognition of cannabis dependency as a clinical condition and rising demand for effective pharmaceutical solutions. Cannabis Use Disorder Market insights also indicate expanding geographic coverage and improved diagnostic screening are catalyzing broader industry adoption, underpinning the sustained market revenue growth over the forecast period.

Current Events & Their Impact on Market

I. Expansion of Medical Cannabis Legalization
A. Regional Legal Reforms - Increasing legalization across North America and Europe is expanding patient access, fueling market growth opportunities through higher treatment uptake.
B. Nano-Level Innovation in Diagnostics - Advances like digital therapeutics in treatment adherence are opening new market dynamics and enhancing therapeutic outcomes.
C. Macro-Economic Healthcare Shifts - Rising healthcare budgets for mental health and addiction services globally support market expansion and business growth in novel Cannabis Use Disorder treatments.

II. Breakthrough Clinical Trials on Novel Therapies
A. Positive Phase III Trial Outcomes - For example, Zynerba Pharmaceuticals' innovative transdermal cannabinoid treatments reported 2024 trial success, boosting investor confidence and market company valuations.
B. Regulatory Approval Accelerations - Faster approvals in regions such as the EU and the U.S. FDA are reshaping market trends, enabling quicker commercialization and broader patient reach.
C. Pharmaceutical Mergers & Acquisitions - Major players are consolidating, driving market consolidation and competitive landscape shifts.

Impact of Geopolitical Situation on Supply Chain

The ongoing geopolitical tensions in Eastern Europe, notably the 2024 logistical disruptions caused by supply chain blockades, have delayed key raw material shipments for cannabinoid-based pharmaceuticals. For instance, a significant delay in exporting phytocannabinoids from Ukraine to Western Europe impacted production cycles for multiple Cannabis Use Disorder market companies, leading to temporary supply shortages and increased manufacturing costs. This real-world scenario underscores how geopolitical instability can restrain market growth and challenge seamless product availability, influencing the overall market scope and revenue generation.

SWOT Analysis

Strengths:
- Robust pipeline of cannabinoid-derived therapies supported by recent clinical trial successes.
- Growing awareness and diagnosis rates driving higher demand and market revenue.
- Strong investments from pharmaceutical companies enhancing R&D capabilities.

Weaknesses:
- Regulatory complexity across jurisdictions limits market expansion speed.
- Limited approved pharmacological treatments restrict extensive patient access in some regions.
- Supply chain vulnerabilities caused by geopolitical tensions affect raw material availability.

Opportunities:
- Expanding legalization of medical cannabis globally creates new market segments.
- Integration of digital health tools offers improved patient management and adherence.
- Market growth strategies focusing on combination therapies may boost treatment efficacy.

Threats:
- Stringent regulatory scrutiny and policy fluctuations might delay approvals.
- Market challenges posed by stigma associated with cannabis-related disorders.
- Competitive pressures from alternative addiction treatment modalities affect market share.

Key Players

- Aelis Farma
- Indivior
- Pfizer
- Corbus Pharmaceuticals
- Zynerba Pharmaceuticals

In 2024 and 2025, several key market players have entered strategic partnerships to accelerate innovation. For example, Pfizer’s collaboration with biotech firms advanced clinical research on synthetic cannabinoids. Zynerba Pharmaceuticals invested heavily in transdermal delivery mechanisms yielding positive phase III trial results. Indivior expanded its portfolio through acquisitions focusing on cannabinoid therapies, thus enhancing its competitive positioning. Collectively, these strategic moves are shaping market trends and fostering continued industry share growth.


FAQs on Cannabis Use Disorder Market

1. Who are the dominant players in the Cannabis Use Disorder market?
Leading companies include Aelis Farma, Indivior, Pfizer, Corbus Pharmaceuticals, and Zynerba Pharmaceuticals, all actively investing in novel cannabinoid-based treatment strategies and R&D.

2. What will be the size of the Cannabis Use Disorder market in the coming years?
The market is projected to grow from USD 1.80 billion in 2025 to USD 3.40 billion by 2032, at a CAGR of 9.5%, indicating strong business growth prospects.

3. Which end-user industry has the largest growth opportunity?
The pharmaceutical and healthcare sectors hold the largest opportunities, driven by increasing diagnosis rates and expanded medical cannabis legalization.

4. How will market development trends evolve over the next five years?
Key trends include the adoption of innovative drug delivery systems, accelerated regulatory approvals, and integration of digital therapeutics enhancing treatment adherence.

5. What is the nature of the competitive landscape and challenges in the Cannabis Use Disorder market?
Competition is intensifying as companies focus on differentiation through advanced therapeutics and clinical advancements, while facing challenges from regulatory barriers and stigma.

6. What go-to-market strategies are commonly adopted in the Cannabis Use Disorder market?
Companies are leveraging strategic partnerships, targeted regulatory navigation, and expanded clinical programs to expedite product launches and maximize market penetration.

‣ Get more insights on : Cannabis Use Disorder Market

‣ Get this Report in Japanese Language: 大麻使用障害市場

‣ Get this Report in Korean Language:   대마사용장애시장

Author Bio:

Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc. (https://www.linkedin.com/in/money-singh-590844163 )